Synthis Therapeutics is a NY biotech company developing the next generation of immunomodulatory antibody drug conjugates (ADCs) for cancer patients. Comprised of an immune cell targeted antibody attached to a non-cytotoxic payload, SYN101 is a first in class, ADC that selectively and safely blocks immune suppression and drives tumor clearance, in multiple tumor models in vivo. We have issued patents on the platform and are currently raising a $35M Series A for IND enabling studies and Phase I trials.